Pharmacokinetics, disposition, and biotransformation of the cardiac myosin inhibitor aficamten in humans
Abstract Aficamten, a cardiac myosin inhibitor, is being developed for the treatment of patients with symptomatic hypertrophic cardiomyopathy (HCM). The purpose of this study was to determine the absorption, metabolism, and excretion of aficamten. Eight healthy male participants received a single or...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Wiley
2024-10-01
|
| Colección: | Pharmacology Research & Perspectives |
| Materias: | |
| Acceso en línea: | https://doi.org/10.1002/prp2.70006 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|